• About Us
    • Leadership
    • Our Supporters
    • IRS Form 990
  • Resources for Your Journey
    • What Is Heart Valve Disease?
  • News & Insights
    • HVV US Patient Journey Report
  • Policy Center
    • HVD Policy Task Force
  • Join Our Community
    • Sign Up For Our Mailing List
    • My Valve. My Voice.
Heart Valve Voice USHeart Valve Voice US
  • About Us
    • Leadership
    • Our Supporters
    • IRS Form 990
  • Resources for Your Journey
    • What Is Heart Valve Disease?
  • News & Insights
    • HVV US Patient Journey Report
  • Policy Center
    • HVD Policy Task Force
  • Join Our Community
    • Sign Up For Our Mailing List
    • My Valve. My Voice.

New Developments Expected in 2019 for Minimally Invasive Valve Treatments

January 3, 2019 Policy Archives

Mitral Valve Positive Findings

A minimally-invasive treatment option for mitral valve regurgitation got a recent boost from a study finding fewer post-treatment hospitalizations for heart failure and also fewer deaths for all reasons. Abbott’s MitraClip is available for patients who are considered high risk for surgery. The valve is third generation technology and is delivered through a catheter inserted into the femoral artery. Click here for a Star Tribune article and here for a MedPageToday article.

New Aortic Valve Under Consideration

A new Transcatheter Aortic Valve Replacement (TAVR) valve called the Lotus Edge, made by Boston Scientific, could receive FDA approval by mid-2019. Benefits of the Lotus Edge are reported to be low rates of paravalvular leak (PVL) as well as reduced need for permanent pacemaker implantation. Click here for more info from Boston Scientific, and here for an article about the possible approval.

Bicuspid Valve Study

The valve maker Medtronic currently is studying low-risk TAVR patients with biscuspid valves, a condition in which a person is born with an aortic valve with only two leaflets instead of three. In the early use of TAVR, persons with a bicuspid aortic valve were disqualified from having a TAVR procedure. Click here to see an article about this clinical trial.

Connect with Trials

Patients interested in participating in clinical trials for low-risk TAVR, TAVR for bicuspid valves, or for mitral valve repair (or for other conditions), can view possibilities here. Antidote states its mission as “accelerat[ing] breakthroughs in potentially life-saving treatments by bridging the gap between medical research and the people who need it.”

Tags: Aortic ValveBicuspid ValveClinical TrialMitral ValveTreatments
Share
2

You also might be interested in

Patient Perspective: Natalie’s Story (Gaithersburg, Maryland)

Nov 12, 2018

Natalie Werber had a Transcatheter Aortic Valve Replacement in 2017[...]

Elderly heart valve patients willing to accept more risks from treatment options to maintain independence

Jun 17, 2019

New study finds that elderly patients would tolerate substantially more[...]

Watch Our Event: A Briefing on Emerging Issues in Mitral Valve Disease

Watch Our Event: A Briefing on Emerging Issues in Mitral Valve Disease

Feb 6, 2020

 Did you miss our briefing on Capitol Hill January[...]

Contact Us

Please contact us with any questions or to get involved.

Send Message
Join the My Valve My Voice patient community Download the app
Sign Up for Our Mailing List

© · Heart Valve Voice

Terms of Use
Privacy Policy

Contact Info

  • Heart Valve Voice US
  • 100 M Street SE 600 Washington, DC 20003
  • info@heartvalvevoice-us.org
  • https://www.heartvalvevoice-us.org
Prev Next